ocket No. LeA 35839

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ecker. et al.

Group No.: 1615

Serial No.:

Examiner:

Filed: 03/25/2005

For: Stable Salts of O-Acetylsalicylic Acid Containing Basic Amino Acids II

#### CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

# TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

### IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the ments.

#### FFF PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

- 1 -

Respectfully submitted,

Reg. No. 31018

Telephone: (203) 812-2712

Date: 14 Sept. 2005

William F. Grav Attorney for Applicant(s) Bayer Corporation

400 Morgan Lane West Haven, CT 06516 2115

OIPE

SEP 1 9 2005

PTO/SB/08A (07-05) Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number. Complete if Known

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) Sheet 1

Application Number 10/501.677 Filing Date 03/25/2005 First Named Inventor Ecker, et al Art Unit 1615 Examiner Name Attorney Docket Number LeA 35839

			U. S. PATENT I	DOCUMENTS	
xaminer nitials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	-	US-	<del></del>		
		03-	1		1
		US-			
		US-			
	_	US-			·
	<del> </del>	US+			
		US-	<del> </del>		<del></del>
		US-	+		·
	-	US+			
	<del> </del>	US-	<del>                                     </del>		
	_	US-	+		
_	-	US-			<del> </del>
		US-			
	_	US-	<del>  </del>		-
		US-			-
		US-			
		US-			
		US-			
		US-			1
		US-	1		<del> </del>

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> 'Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	To.
		WO 02/05702 A2	01-24-2002	Franckowiak, et al.		
		ALREADY LISTED	IN PREVI	OUS IDS.		
	-					Н
-	-					Щ
	Щ,	<u></u>				$\Box$

Examiner Signature	/Chris Simmons/	Date Considere	d 07/13/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in co-considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*S \*EXAMINE: Initial if reference considered, whether or not custom is in considered. Include copy of this form with next communication to applicant. Propiocar's unique citation designation number (optional). "See Kinds Codes or USPTO Patent Documents a www.uspto.gov or WPEP 901.04." Eleter Office that issued the document, by the two-letter code (WPD Standard ST.31." For applications of the work of the comments, the indication of the year of the regine of the Emperor must periods the secial number of the patent document. Whether the comments are indicated in the Advanced under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English language <sup>2</sup>See Kinds Codes of Standard ST.3), <sup>4</sup> For

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comon the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it contains a valid OMB control number. Complete if Known for form 1449/PTO **Application Number** 10/501,677 NFORMATION DISCLOSURE Filing Date 03/25/2005 STATEMENT BY APPLICANT First Named Inventor Ecker, et al. Art Unit 1615 (Use as many sheets as necessary) Examiner Name Sheet 2 12 Attorney Docket Number LeA 35839

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		90HMIDT, P. O., and CHRISTIN, I., Wirk- and Hilfsstoffe for Rezeptor, Defektor and Greenhorstellung, Wissinschaftliche Verlagsgesellschaft, Stuttgart (1999).	
/C.S./		MOLL, F., and STAUFF, D., Wechselwirkungen zwischen Acetylsalicylsaure und Lysin in Losung; Arch. Pharm. 318, 120-127 (1985).	
/C.S./		RASCHKA, C., and KOCH, H., Pharmakokinetik und Pharmakodynamik der peroralen und intravenosen Gabe von D. L-Lysinacetylsalicylat und der oralen Gabe von Acetylsalicylat; Perfusion, 13, 262-268 (2000).	
		ONLY ENGLISH ABSTRACT CONSIDERED FOR MOLL ET AL.	
		AND RASCHKA ET AL. DOCUMENTS MUST BE IN ENGLISH TO BE CONSIDERED.	

Examiner Signature	/Chris Simmons/	Date Considered	07/13/2008

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant is unjue obtation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). A Applicant is to below a check mark here if English injuryage Transistion is attached.

This societion of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO Text 1990). The information is required to obtain or retained to be the control of the control of the complex including publicing, preparing, and susmitting the complexing application form as the USPTO. Then the control of the complexing and susmitting the complexing application form as the USPTO. The control of the complexing application form as the USPTO. The control of the complexing application formation of the complex application formation of the complexing application formation of the complex application formation of the complex application formation of the complex application formation application formation of the complexing application formation application

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.